肝细胞癌检出中肝胆对比剂与细胞外对比剂MRI的比较:肝胆期特征与无病生存的关系
回顾性纳入2014年1月至2015年12月接受术前增强肝脏MRI并根治性切除的170例初治肝细胞癌患者,比较使用肝胆对比剂与细胞外对比剂两组患者的无病生存率,并将肝胆对比剂组按术后是否残留肝胆期低信号结节(无动脉期高强化)分为阳性组与阴性组。中位随访34.1个月,细胞外对比剂组与肝胆对比剂组中位无病生存期无显著差异(35.8个月 vs 43.5个月,P=0.46);但细胞外对比剂组中位无病生存期长于低信号结节阳性组(35.8个月 vs 25.8个月,P<0.001),短于低信号结节阴性组(35.8个月 vs 48.6个月,P=0.02)。结论提示术前使用肝胆对比剂MRI并切除无动脉期高强化的肝胆期低信号结节的患者可能获得更好的无病生存。
要点
- 术前肝胆对比剂MRI组与细胞外对比剂组的中位无病生存期无显著差异(43.5个月 vs 35.8个月,P=0.46)。
- 肝胆对比剂组中,术后残留肝胆期低信号结节(无动脉期高强化)阳性者中位无病生存期较短(25.8个月 vs 阴性组48.6个月)。
- 细胞外对比剂组中位无病生存期长于低信号结节阳性组(35.8个月 vs 25.8个月,P<0.001),短于低信号结节阴性组(35.8个月 vs 48.6个月,P=0.02)。
核心结论
- 术前使用肝胆对比剂MRI并切除无动脉期高强化的肝胆期低信号结节的患者可能显示更好的无病生存。
研究设计与样本
- 回顾性纳入2014年1月至2015年12月170例初治肝细胞癌患者,均接受术前增强肝脏MRI及根治性肝切除,随访至2018年9月;按所用MRI对比剂分为细胞外对比剂组(n=53;平均年龄60岁±9)与肝胆对比剂组(n=117;平均年龄60岁±8),后者再按术后有无残留肝胆期低信号结节(无动脉期高强化)分为阳性组(n=26)与阴性组。
关键影像表现/征象
- 肝胆期低信号结节指无动脉期高强化的残留低信号病灶,阳性组中位无病生存期25.8个月。
- 肝胆期低信号结节阴性组中位无病生存期48.6个月,长于细胞外对比剂组的35.8个月(P=0.02)。
诊断标准与关键数值
- 分组依据为术前MRI所用对比剂类型(细胞外对比剂 vs 肝胆对比剂)。
- 肝胆对比剂组进一步按术后是否存在无动脉期高强化的肝胆期低信号结节分为阳性组与阴性组。
- 无病生存率采用Kaplan-Meier法计算,三组间比较采用log-rank检验。
临床应用与阅片要点
- 阅片时需注意肝胆期低信号且无动脉期高强化的结节,该征象与术后无病生存相关。
- 报告肝胆对比剂MRI时,可描述是否存在无动脉期高强化的肝胆期低信号结节,供临床参考。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background MRI with hepatobiliary contrast material is more sensitive than MRI with extracellular contrast material in the detection of hepatocellular carcinoma (HCC). Purpose To determine whether postsurgical outcomes differ between patients who undergo MRI with hepatobiliary contrast material and those who undergo MRI with extracellular contrast material by analyzing disease-free survival (DFS) rates after curative resection of HCC. Materials and Methods From January 2014 to December 2015, 170 treatment-naïve patients who underwent contrast-enhanced preoperative liver MRI and curative hepatic resection for HCC were retrospectively included and observed until September 2018. DFS rates were compared between the two groups, which were classified based on the type of MRI contrast agent used. The MRI with hepatobiliary contrast material group was further divided into a hypointense nodule-positive group and a hypointense nodule-negative group according to the presence of residual hepatobiliary phase (HBP) hypointense nodules without arterial phase hyperenhancement (APHE) after surgery. DFS rates were calculated by using the Kaplan-Meier method and were compared among the three groups by using a log-rank test. Results Patients were included in either the MRI with extracellular contrast material group (n = 53; mean age, 60 years ± 9 [standard deviation]) or the hepatobiliary contrast material group (n = 117; mean age, 60 years ± 8; 26 patients were in the hypointense nodule-positive group). Over a median follow-up period of 34.1 months, median DFS rates did not differ between the extracellular contrast material group (35.8 months) and the hepatobiliary contrast material group (43.5 months) (P = .46). However, median DFS in the extracellular contrast material group was longer than that in the hypointense nodule-positive group (35.8 months vs 25.8 months, P < .001) and shorter than that in the hypointense nodule-negative group (35.8 months vs 48.6 months, P = .02). Conclusion Patients who undergo preoperative MRI with hepatobiliary contrast material and resection of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement may show better disease-free survival. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Motosugi in this issue.
引用
- Kim DK, An C, Chung YE, et al. Hepatobiliary versus Extracellular MRI Contrast Agents in Hepatocellular Carcinoma Detection: Hepatobiliary Phase Features in Relation to Disease-free Survival. Radiology. 2019. PMID: 31592730. doi:10.1148/radiol.2019190414
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。